A study to evaluate the use and safety of intralesional MMR vaccine in molluscum contagiosum
Not Applicable
- Conditions
- Health Condition 1: B081- Molluscum contagiosum
- Registration Number
- CTRI/2022/12/048166
- Lead Sponsor
- A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Patients aged > 12 years, irrespective of sex.
2.Immunocompetent
3.Having more than 10 MC lesions
4.Consenting patients.
Exclusion Criteria
1.Participants those who had history of any life-threatening allergies
2.Pregnant and lactating mothers
3.Severe organ dysfunction/ immunosuppression.
4.Family history of severe immune dysfunction
5.Fever, or any signs of local or systemic infection.
6.Patients with tuberculosis, HIV, Hepatitis B and Hepatitis C
7.Those who cannot provide consent for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients showing complete clearance of molluscum contagiosum lesions at 12 weeks follow up in both arms.Timepoint: At the end of 12 weeks in both arms (i.e., at the end of 6 weeks after 3rd injection received).
- Secondary Outcome Measures
Name Time Method 1.Proportion of patients showing at least 50% reduction in lesion count at 12 weeks follow up in both arms. <br/ ><br>2.To evaluate the safety profile and documentation of adverse effects of intralesional MMR vaccine in MC patients <br/ ><br>Timepoint: At the end of 12 weeks in both arms(i.e., at the end of 6 weeks after receiving 3rd injection)